DPFS Resource Request (University of Birmingham)

Lead Research Organisation: University of Birmingham
Department Name: Clinical and Experimental Medicine

Abstract

Medical research in the UK aims to find new ways of treating and diagnosing people with disease. It is important that when new medical innovations are made, steps are taken to ensure that this knowledge is exploited to its full potential and is able to make the transition from the laboratory into patient healthcare application. This proposal asks for resource to support the management of a portfolio of such innovations within the University of Birmingham, currently at an early stage of development, through to a stage where they can receive further investment and be effectively translated into new healthcare opportunities.

Technical Summary

This project focuses on providing key support to nine commercialisation cases, which have been identified from the College IP portfolio, prior to future application for DPFS funding. A Technology Transfer Officer is requested to provide dedicated project management/development support and expertise to advance DPFS projects across the College?s portfolio of activity. It is also proposed that a flexible consultancy approach is employed to buy in external subject/sector/commercial expertise to ensure that innovative and commercially and/or health service relevant approaches are used to achieve successful exploitation and application of the new innovations arising from the College. This approach will provide the necessary resource and expertise to ensure proposals are developed which are commercially focused and have clearly defined and achievable translational objectives and endpoints. The new resource will work with and complement existing Technology Transfer support available within the College and across the University of Birmingham, to provide seamless support for Translational research.

Publications

10 25 50
 
Description Developmental Clinical Study
Amount £750,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2011 
End 06/2013
 
Description FPD1
Amount £99,242 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2009 
End 11/2010
 
Title ANTI-CANCER COMPOSITION COMPRISING ALGINATE 
Description The present invention relates to a biologically acceptable composition for the prophylaxis and/or treatment of colorectal cancer comprising an iron chelator, wherein the composition is adapted for the selective targeting of the iron chelator to the colon. 
IP Reference WO2011051665 
Protection Patent application published
Year Protection Granted 2011
Licensed No
Impact None
 
Title BIOMARKER 
Description A method of diagnosing or determining the degree of an arterial aneurysm, especially an abdominal aortic aneurysm, which comprises determining the presence or level of interleukin-1a (IL-1aa) in a serum or plasma sample. 
IP Reference WO2011141746 
Protection Patent application published
Year Protection Granted 2011
Licensed No
Impact Discussion with industry experts to identify new funding opportunities and develop towards these, including MRC DPFS.
 
Title IMMUNE ASSAY 
Description The invention relates to a method of identifying a modulator of the immune response system, comprising assaying for the effect of a compound on the internalisation and recycling of CTLA-4 in a cell, wherein an increase in cycling of CTLA-4 compared to a control without the compound indicates that the compound suppresses the immune response and a decrease in the cycling of CTLA-4 compared to a control without the compound, indicates that the compound increases the immune response. The cycling of CTLA-4 may be determined by monitoring CTLA-4 or monitoring uptake of a CTLA-4 label into a cell. 
IP Reference WO2012127240 
Protection Patent application published
Year Protection Granted 2012
Licensed No
Impact Further industrial discussions to identify future collaborative opportunities for lead academic.
 
Title METHODS AND PRODUCTS 
Description The present invention provides improved methods for measuring the ratio of free K immunoglobulin light chain molecules to free ? immunoglobulin light chain molecules in a test sample, using a monoclonal antibody that specifically binds to free K and a monoclonal antibody that specifically binds to free ?. The application also provides specific monoclonal antibodies that can be used in the method of the invention, as well as kits containing said monoclonal antibodies. 
IP Reference WO2010049672 
Protection Patent application published
Year Protection Granted 2010
Licensed Yes
Impact Development of a near patient test
 
Title NON-TYPHOIDAL SALMONELLA VACCINES 
Description a vaccine candidate for salmonella 
IP Reference EP2324051 
Protection Patent application published
Year Protection Granted 2011
Licensed Yes
Impact None
 
Title PREBIOTIC AGENT 
Description A composition for the improvement of gastrointestinal health and/or for the improvement of a gastrointestinal bacterial population is provided. The composition comprises a prebiotic, is adapted for selective targeting of the prebiotic to the colon and is substantially free from probiotic. 
IP Reference WO2012146890 
Protection Patent application published
Year Protection Granted 2012
Licensed No
Impact Further interactions with potential industry partners for lead academic
 
Title RE-DIRECTED IMMUNOTHERAPY 
Description The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells. 
IP Reference WO2012123755 
Protection Patent application published
Year Protection Granted 2012
Licensed No
Impact Further discussions with industry representatives for lead academic to identify future funding opportunities
 
Title SCREENING METHOD 
Description The present invention relates to clinical diagnosis of Alzheimer's disease or early- stage Alzheimer's disease in the live patient. In particular, the invention provides a screening method which can be used to assist with diagnosis of Alzheimer's disease in live human subjects, or to identify human subjects with a predisposition to Alzheimer's disease. 
IP Reference WO2011007155 
Protection Patent application published
Year Protection Granted 2011
Licensed No
Impact None
 
Title THERAPEUTIC USES OF DIARYLALKANES SUCH AS MITOTANE 
Description The present invention provides a compound of formula (30) for use in the treatment of a 5a-reductase-mediated condition in a human or animal: where X1 and X2 are independently selected from H, halogen, substutituted or unsubstituted amino, hydroxyl, C1-C6 alkoxy, substutituted or unsubstituted carboxylate, substituted or unsubstituted C1-C6 alkyl, substutituted or unsubstituted C2-C6 alkenyl, substutituted or unsubstituted C2-C6 alkynyl, or substutituted or unsubstituted aryl; and Ar1 and Ar2 are independently selected from substutituted or unsubstituted aryl. 
IP Reference WO2012110768 
Protection Patent application published
Year Protection Granted 2012
Licensed No
Impact N/A
 
Description Workshops and information events 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Internal staff have attended an annual Business Ideas competition to learn more about commercialisation and the funding available

Increased awareness of the MRC DPFS scheme
Year(s) Of Engagement Activity 2009,2010